Why the study?
Are ADMA and homocysteine levels associated with carotid intima-media thickness in patients with end-stage renal disease on haemodialysis?
Cross-Sectional (n=30)
Are ADMA and homocysteine levels associated with carotid intima-media thickness in patients with end-stage renal disease on haemodialysis?
ADMA may serve as a novel marker of atherosclerosis in patients on haemodialysis, as it independently correlates with carotid intima-media thickness.
OBJECTIVE: This cross-sectional study explored the association between carotid intima-media thickness (CIMT) and the oxidative stress markers asymmetric dimethylarginine (ADMA) and homo cysteine in patients with end-stage renal disease who were on haemodialysis. METHODS: A total of 30 patients undergoing chronic haemodialysis treatment were recruited to this study. Homocysteine and ADMA levels were determined using a fluorescence polarization immunoassay and an enzyme-linked immunosorbent assay, respectively. CIMT was measured as a marker of atherosclerosis using high-resolution ultrasonography and was performed after haemodialysis. RESULTS: Significant positive correlations were found between CIMT and ADMA, and CIMT and duration of haemodialysis. Linear regression analysis showed that ADMA level and age were significant independent determinants of CIMT, whereas homo cysteine was not. CONCLUSIONS: The relationship demonstrated between plasma ADMA and carotid artery thickening suggests that ADMA may be a novel marker of atherosclerosis in patients on haemodialysis.
No takes yet. Share an insight, caveat, or question.
Thaha et al. (2012) conducted a cross-sectional in End-stage renal disease (n=30). Asymmetric dimethylarginine (ADMA) was evaluated on Carotid intima-media thickness (CIMT).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: